荣昌生物
(688331)
| 流通市值：147.27亿 | | | 总市值：511.64亿 |
| 流通股本：1.62亿 | | | 总股本：5.64亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 1,273,915,008.95 | 721,718,278.96 | 762,492,395.54 | 664,964,952 |
| 交易性金融资产 | 9,171,261.22 | - | - | 260,179,555.56 |
| 应收票据及应收账款 | 549,710,992.32 | 535,574,498.81 | 587,688,671.37 | 482,106,303.7 |
| 其中：应收票据 | 194,385,130.59 | 203,611,667.29 | 204,299,928.35 | 147,677,318.74 |
| 应收账款 | 355,325,861.73 | 331,962,831.52 | 383,388,743.02 | 334,428,984.96 |
| 应收款项融资 | 11,880,522.64 | 10,876,421.81 | 11,097,822.85 | 51,264,381.26 |
| 预付款项 | 181,044,440.89 | 211,678,254.07 | 241,373,752 | 287,105,369.05 |
| 其他应收款合计 | 28,447,508.3 | 38,016,784.67 | 24,283,132.94 | 29,200,438.94 |
| 存货 | 641,247,289.43 | 638,250,683.99 | 659,368,730.71 | 745,387,541.34 |
| 其他流动资产 | 2,743,063.99 | 4,672,775.16 | 3,491,867.9 | 3,798,780.51 |
| 流动资产合计 | 2,698,160,087.74 | 2,160,787,697.47 | 2,289,796,373.31 | 2,524,007,322.36 |
| 非流动资产: | | | | |
| 长期股权投资 | 8,737,936.81 | 8,724,070.05 | 8,850,723.9 | 8,850,545.83 |
| 其他权益工具投资 | 94,792,886.55 | 71,451,198.74 | 59,313,437.97 | 53,840,867.96 |
| 其他非流动金融资产 | 5,037,475.88 | 5,037,475.88 | 4,037,475.88 | 3,038,731.56 |
| 固定资产 | 2,367,746,020.86 | 2,415,481,681.93 | 2,457,180,322.07 | 2,412,993,585.31 |
| 在建工程 | 406,420,464.56 | 274,386,452.19 | 283,231,455.78 | 309,112,443.03 |
| 使用权资产 | 62,762,795.54 | 77,016,451.12 | 93,753,714.63 | 108,139,896.18 |
| 无形资产 | 153,902,186.39 | 144,283,335.84 | 143,131,261.71 | 142,680,567.46 |
| 长期待摊费用 | 2,492,190.55 | 3,436,262.42 | 4,324,896.83 | 5,493,772.56 |
| 其他非流动资产 | 50,306,072.04 | 146,740,422.38 | 154,898,506.74 | 144,555,680.75 |
| 非流动资产合计 | 3,152,198,029.18 | 3,146,557,350.55 | 3,208,721,795.51 | 3,188,706,090.64 |
| 资产总计 | 5,850,358,116.92 | 5,307,345,048.02 | 5,498,518,168.82 | 5,712,713,413 |
| 流动负债: | | | | |
| 短期借款 | 1,320,553,083.34 | 1,131,441,051.38 | 1,083,853,548.13 | 1,026,766,746.38 |
| 应付票据及应付账款 | 209,201,828.9 | 183,333,479.65 | 162,250,106.68 | 184,834,362.99 |
| 应付账款 | 209,201,828.9 | 183,333,479.65 | 162,250,106.68 | 184,834,362.99 |
| 合同负债 | 1,265,886.69 | 3,464,453.46 | 3,143,688.86 | 3,220,361.43 |
| 应付职工薪酬 | 195,162,276.35 | 202,014,930.29 | 209,986,022.76 | 199,275,853.26 |
| 应交税费 | 30,074,215.92 | 36,662,017.3 | 37,058,544.84 | 40,837,332.71 |
| 其他应付款合计 | 267,878,981.77 | 276,552,827.94 | 314,995,392.79 | 272,540,452.82 |
| 一年内到期的非流动负债 | 508,021,662.64 | 500,378,057.66 | 348,684,938.4 | 118,158,847.27 |
| 其他流动负债 | 15,736,850.57 | 11,108,272.72 | 18,324,410.71 | 15,154,007.15 |
| 流动负债合计 | 2,547,894,786.18 | 2,344,955,090.4 | 2,178,296,653.17 | 1,860,787,964.01 |
| 非流动负债: | | | | |
| 长期借款 | 816,730,338.19 | 1,063,318,088.45 | 1,195,878,046.86 | 1,341,279,937.63 |
| 租赁负债 | 29,236,692.56 | 33,902,632.34 | 42,093,510.05 | 46,536,564.21 |
| 递延收益 | 91,966,536.39 | 93,744,141.76 | 96,049,337.8 | 95,428,408.34 |
| 递延所得税负债 | 7,039,192.51 | - | - | - |
| 非流动负债合计 | 944,972,759.65 | 1,190,964,862.55 | 1,334,020,894.71 | 1,483,244,910.18 |
| 负债合计 | 3,492,867,545.83 | 3,535,919,952.95 | 3,512,317,547.88 | 3,344,032,874.19 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 563,608,243 | 544,332,083 | 544,332,083 | 544,332,083 |
| 资本公积 | 6,960,504,191.9 | 6,281,946,295.16 | 6,290,989,900.9 | 6,287,590,554.06 |
| 减:库存股 | 343,271,955.74 | 408,910,121.8 | 445,329,702.16 | 444,896,381.34 |
| 其他综合收益 | -51,910,054.43 | -69,927,500.66 | -81,920,470.23 | -93,408,689.99 |
| 未分配利润 | -4,771,439,853.64 | -4,576,015,660.63 | -4,321,871,190.57 | -3,924,937,026.92 |
| 归属于母公司股东权益合计 | 2,357,490,571.09 | 1,771,425,095.07 | 1,986,200,620.94 | 2,368,680,538.81 |
| 股东权益合计 | 2,357,490,571.09 | 1,771,425,095.07 | 1,986,200,620.94 | 2,368,680,538.81 |
| 负债和股东权益合计 | 5,850,358,116.92 | 5,307,345,048.02 | 5,498,518,168.82 | 5,712,713,413 |
| 公告日期 | 2025-08-23 | 2025-04-29 | 2025-03-28 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |